Evidence map›Paper›PMID 39188347›Full record

ReviewSmart medicine2023

Emerging antibacterial nanozymes for wound healing.

Jingyang Shan, Junyi Che, Chuanhui Song, Yuanjin Zhao

Abstract readReview
In one paragraph

Review in Smart medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jingyang ShanDepartment of Rheumatology and Immunology Nanjing Drum Tower Hospital State Key Laboratory of Bioelectronics School of Biological Science and Medical Engineering Southeast University Nanjing China.ORCID https://orcid.org/0000-0002-9241-7617
Junyi CheDepartment of Rheumatology and Immunology Nanjing Drum Tower Hospital State Key Laboratory of Bioelectronics School of Biological Science and Medical Engineering Southeast University Nanjing China.
Chuanhui SongDepartment of Rheumatology and Immunology Nanjing Drum Tower Hospital State Key Laboratory of Bioelectronics School of Biological Science and Medical Engineering Southeast University Nanjing China.
Yuanjin ZhaoDepartment of Rheumatology and Immunology Nanjing Drum Tower Hospital State Key Laboratory of Bioelectronics School of Biological Science and Medical Engineering Southeast University Nanjing China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wound infections continuously impose a huge economic and social burden on public healthcare. Despite the effective treatment of bacteria-infected wounds after using traditional antibiotics, the misuse of antibiotics usually causes the spread of bacterial resistance and decreases therapeutic outcomes. Therefore, the development of efficient antibacterial agents is urgently needed. Nanozymes, as a new generation of artificial enzymes, combine the intrinsic abilities of nanomaterials and natural enzymes. Recently, nanozymes has been widely developed to kill bacteria and treat wound infections by catalyzing the generation of various reactive oxygen species. Thus, this new concept of "antibacterial nanozymes" will promote the further advances of connecting nanozymes and bacterial elimination. To highlight these achievements, we summarize different types of antibacterial nanozymes for wound healing. It is believed that such a promising therapeutic strategy of developing antibacterial nanozymes will make a great contribution in the field of skin regeneration. We expect that antibacterial nanozymes will play the significant roles in both basic research and clinical applications.

Indexed as

bacteriananozymesreactive oxygen speciesskin regenerationwound

Identifiers

PMID39188347
PMCPMC11235951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.